News Formal

Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 97%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

An Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.

Amgen Inc.’s disclosure Wednesday of a large stake in Neumora Therapeutics Inc. indicates that the value of its investment in the biopharmaceutical company, which recently went public, has tripled.

The 13D said Amgen’s investment started with the purchase of preferred shares for about $110 million and the grant of certain exclusive license rights, which was announced by the company’s in October 2021. That means Amgen has spent about $140 million to acquire its Neumora stake. Based on Tuesday’s closing price $11.71 for Neumora’s stock, Amgen’s stake was worth $414.2 million, or 195.8% more than what the company spent.The stock closed its first day of trading on Sept. 15 at $16.25, or 4.4% below its IPO price. It closed as low as $10.13, or 40.4% below the IPO price, on Sept. 20 before bouncing over the past four sessions.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Amgen Could Get a Piece of the Obesity MarketAmgen has a couple of shots on goal to break into one of the biggest markets the pharmaceutical industry has ever seen.
Source: WSJ - 🏆 98. / 63 Read more »

Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trialPliant Therapeutics Inc. shares gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic...
Source: MarketWatch - 🏆 3. / 97 Read more »

Czech giant takes major stake in CoronadoCzech Republic-based Sev.en Global Investments has struck a deal to acquire a 51% interest in ASX-listed coal miner Coronado Global Resources from founding company The Energy & Minerals Group (EMG). No details of the transaction were released, but Coronado told shareholders this week that the acquisition was subject to customary closing conditions, including regulatory approvals in the US and Australia.
Source: MiningWeeklyAUS - 🏆 233. / 63 Read more »